Testosterone replacement therapy on male late-onset hypogonadism with Mild-to-moderate benign prostate hy-perplasia
10.11659/jjssx.11E014026
- VernacularTitle:TRT在男性迟发性性腺功能减退症伴轻中度前列腺增生的应用
- Author:
Gang ZHOU
;
Jingluo PENG
;
Xingsheng LIU
;
Qing JIANG
- Publication Type:Journal Article
- Keywords:
tesosterone replacement therapy;
benige prostate hyperplasia;
late-onset hypogonadism
- From:Journal of Regional Anatomy and Operative Surgery
2015;(1):73-75,76
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the safety and efficacy of testosterone replacement therapy in patients with male late-onset hypogon-adism and Mild-to-moderate benige prostate hyperplasia. Methods Forty-three patients diagnosed as male late-onset hypogonadism and Mild-to-moderate benige prostate hyperplasia were selected,of which 28 patients were assigned to Eleven acid testosterone (40 mg each time, after a meal,2 times per day) ,other patients were in the control group. The patients were followed for 12 months and their data about digital rectal inspection,size of the prostate,IPSS score,maximum urinary flow rate ( Qmax) ,AMS clinical symptom score,serum testosterone level, serum PSA level,RBC hematocrit ( HCT) ,and other indicators were collected. Results Twelve months After testosterone replacement thera-py,both the prostate volume of treated and control groups were not significantly changed(P>0. 05). IPSS score and maximum urinary flow rate in treatment group were improved significantly(P<0. 05),but the control group showed no statistically significant changes(P>0. 05). Baseline AMS clinical symptom score and blood testosterone level were similar between treatment and control group (P >0. 05). Twelve months after treatment,the blood testosterone level of the treatment group reached the normal range,and the AMS clinical symptom scores de-creased significantly (P<0. 05). However,none indexes of control group significantly changed after the treatment (P>0. 05). Conclusion Testosterone replacement therapy in patients with male late-onset hypogonadism and the Mild-to-moderate benige prostate hyperplasia is safe and effective.
